Synlogic Therapeutics Annual Revenue, Number of Employees, Growth and Funding

Claim your profile


Boston, MA USA
Total Funding:$176.9M
Lead Investor(s):Leerink Partners
Claim your profile

City Ranking

Industry Ranking

State Ranking

Estimated Revenue & Financials

  • Synlogic Therapeutics's estimated annual revenue is currently $13.3M per year.
  • Synlogic Therapeutics received $30.0M in venture funding in April 2018.
  • Synlogic Therapeutics's estimated revenue per employee is $155,000
  • Synlogic Therapeutics's total funding is $176.9M.

Employee Data

  • Synlogic Therapeutics has 86 Employees.
  • Synlogic Therapeutics grew their employee count by -4% last year.
  • Synlogic Therapeutics currently has 1 job openings.

Executive Contacts

Chang HongCorporate Counsel & Head Of Intellectual Property
Aoife BrennanCeo
Caroline KurtzSvp,head Of Metabolism
Ning LiPrincipal Scientist
Michael SlaterHead Of Regulatory Affairs
Brad SmithAssociate Director, Fp&a Lead
Kip WestDirector Of Immunomodulation
Katherine HeangIn Vivo Operations Manager
Philippa ReederUpstream Team Leader - Principal Scientist
Tracy KaneDirector, Interim Program Leader

At Synlogic, we are dedicated to bringing innovative medicines to patients by driving the convergence of two revolutionary fields: synthetic biology and the microbiome. Using our synthetic biotics platform, we are engineering probiotic bacteria to perform specific therapeutic functions with established links to disease. We can deliver these synthetic biotics orally, where they act from the gut microbiome to correct missing or dysfunctional metabolic activities throughout the body. We also aim to deliver synthetic biotics at the site of disease in cases where local activity is critical, as in stimulation of immune effectors to combat certain tumors. We can rapidly translate this groundbreaking science and technology into medicines that have the potential to change the lives of patients. Our lead programs target patients with rare genetic metabolic diseases, including urea cycle disorders (UCD) and phenylketonuria (PKU). We are also hard at work on synthetic biotics to address more prevalent conditions, including inflammatory bowel disease (IBD), cancer and metabolic conditions such as diabetes and obesity. Learn more on our website at



Number of Employees


Revenue (est)


Current Jobs


Employee Growth %


Total Funding







NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Ohana Bioscienc...
Tango Therapeut...
Compass Therape...
Hamilton Storag...
Alnylam Pharmac...
Berkshire Corpo...
Repligen Corpor...
Allena Pharmace...

Synlogic Therapeutics News

09/06/2019 - Synlogic Announces Appointments of New CMO, Head of ...

Synlogic, Inc. (SYBX), a clinical stage company applying synthetic ... its ability to advance these novel therapeutics into clinical trials,” stated Dr.

09/04/2019 - Synlogic Presents Data from Phase 1/2a Study of SYNB1618 ...

Synlogic has initiated a bridging study of a new solid formulation of ... to deliver novel medicines designed to perform a therapeutic function.”.

09/06/2019 - Synlogic (SYBX) Names New CMO, Head of Regulatory ...

Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying ... its ability to advance these novel therapeutics into clinical trials,” stated Dr.

Synlogic Therapeutics Funding

DateAmountRoundLead InvestorsReference
2014-10-08$5.0MABill & Melinda GatesArticle
2016-02-18$40.0MBOrbiMed HealthCare Fund ManagementArticle
2018-01-25$UndisclosedUndisclosedLeerink PartnersArticle
2018-04-09$30.0MUndisclosedLeerink PartnersArticle

Synlogic Therapeutics Executive Hires

2015-05-22Jose-Carlos Gutiérrez-RamosPresident/CEOArticle
2015-09-18Bharatt ChowriraPresidentArticle
2016-12-16Samantha TruexCOO /Head of Corporate Development.Article
2017-10-11Andrew GengosCOO/Head of Corporate DevelopmentArticle
2018-05-11Aoife BrennanInterim President/CEOArticle
2018-10-03Aoife BrennanPresident & CEOArticle
2018-12-13Antoine AwadHead of Technical OperationsArticle

Synlogic Therapeutics Acquisitions

DateCompany NameAmountNotesReference
2017-05-17Mirna Therapeutics Inc.Article
2017-08-29Mirna Therapeutics Inc.Article